8-K: Traws Pharma's Ratutrelvir Shows Positive Phase 2 COVID Data

Traws Pharma announced positive interim Phase 2 data for its ritonavir-free COVID-19 treatment, ratutrelvir, showing a differentiated profile versus PAXLOVID.

Summary

• Interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir in patients with mild-to-moderate COVID-19 were announced.
• The study is designed as an active-controlled comparator trial versus PAXLOVID (nirmatrelvir/ritonavir) and includes a separate treatment arm for PAXLOVID-ineligible patients.
• The interim analysis included 37 patients: 25 treated with ratutrelvir (600 mg orally once daily for 10 days) and 12 treated with PAXLOVID (nirmatrelvir 300 mg plus ritonavir 100 mg twice daily for 5 days).
• Over 50% of the planned 90-patient population has been enrolled.
• Ratutrelvir-treated patients demonstrated time-to-sustained symptom alleviation and resolution numerically comparable to PAXLOVID-treated patients.
• No COVID-19 symptom or virologic rebound events have been observed in ratutrelvir-treated patients to date.
• One rebound event was observed in the PAXLOVID comparator arm (1 of 12 patients; 8.3%).
• Six patients (16.2% of the interim population; 24% of the ratutrelvir cohort) treated with ratutrelvir were ineligible for PAXLOVID due to contraindications or drug-drug interaction risk, and they showed consistent symptom improvement.
• Ratutrelvir was well tolerated, with fewer reported adverse events compared to the PAXLOVID-treated cohort.
• The most common adverse event for ratutrelvir was mild dyspepsia, reported in 2 patients (7.6%), with no dysgeusia or ritonavir-associated adverse effects reported.
• Adverse events commonly associated with PAXLOVID, including dysgeusia, dizziness, and dyspepsia, were reported in 4 patients (30%) in the comparator arm.
• Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to be used without ritonavir, avoiding ritonavir-associated drug-drug interactions.
• Phase 1 data showed ratutrelvir's pharmacokinetic profile maintained target blood plasma levels approximately 13 times above the EC50 using the target Phase 2 dosing regimen of 600 mg/day for ten days.

Sentiment

Score: 8

Explanation: The interim Phase 2 data for ratutrelvir are highly positive, showing comparable efficacy to PAXLOVID, a superior safety and tolerability profile, and addressing a critical unmet need for PAXLOVID-ineligible patients. The absence of viral rebound is a significant advantage. While preliminary, these results are very encouraging for the drug's future development and market potential.

Positives

• Ratutrelvir demonstrated positive interim data in a Phase 2 study for newly diagnosed COVID subjects.
• The drug showed activity in PAXLOVID-ineligible patients, representing a significant population with few effective treatment options.
• Ratutrelvir exhibited a differentiated clinical profile versus PAXLOVID with fewer adverse events.
• No viral rebound events were observed in ratutrelvir-treated patients, compared to one (8.3%) in the PAXLOVID arm.
• A favorable tolerability profile was observed, with only mild dyspepsia reported in 7.6% of ratutrelvir patients and no treatment discontinuations due to adverse events.
• The ritonavir-free administration and once-daily oral dosing offer significant advantages in patient convenience and applicability.
• The combination of early and sustained symptom improvement, extended dosing duration, and absence of viral rebound supports its potential utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID).
• Phase 1 data indicated that ratutrelvir's pharmacokinetic profile maintained target blood plasma levels approximately 13 times above the EC50, which may reduce the likelihood of clinical rebound and Long COVID risk.

Negatives

• The interim data are preliminary, descriptive, and non-inferential, meaning no formal statistical comparisons were performed.
• Not all patients had completed the full 28-day observation period at the time of the interim analysis.
• Completion of enrollment and follow-up for the ongoing study is required to support statistically robust conclusions.

Risks

• Forward-looking statements involve substantial risks and uncertainties, and actual results could differ from expectations.
• The success and timing of Traws' clinical trials, including the reporting of final data analysis for the Phase 2 studies of ratutrelvir, are uncertain.
• There is no guarantee regarding the potential efficacy of ratutrelvir for the treatment of COVID-19, including for PAXLOVID-ineligible patients.
• Uncertainty exists regarding ratutrelvir's potential to gain market acceptance or become the new standard of care if regulatory approval is obtained.
• Risks are associated with Traws' interactions with regulatory bodies such as the FDA, BARDA, and similar foreign regulators.
• Collaborations, market conditions, and regulatory requirements and pathways for approval pose risks.
• The company's ability to raise additional capital when needed is a risk factor.
• Other risks are set forth in Traws' filings with the U.S. Securities and Exchange Commission (SEC).

Future Outlook

Traws Pharma believes the interim data position ratutrelvir as a next-generation oral 3CL protease inhibitor with ritonavir-free administration, once-daily oral dosing, an improved tolerability profile, applicability to PAXLOVID-ineligible populations, and potential relevance to Long COVID prevention strategies. The company expects to report final data analysis in January 2026.

Management Comments

• "These interim data suggest that ratutrelvir may provide a meaningful benefit across a broader range of patients, including those who are unable to receive ritonavir-boosted therapy." Robert Redfield, MD, Chief Medical Officer, Traws Pharma.
• "The favorable tolerability profile observed to date, together with the absence of viral rebound events in ratutrelvir-treated patients, is encouraging." Robert Redfield, MD, Chief Medical Officer, Traws Pharma.
• "While these findings are preliminary and descriptive, they support continued clinical evaluation of ratutrelvir in both acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes." Robert Redfield, MD, Chief Medical Officer, Traws Pharma.
• "The combination of early and sustained symptom improvement, extended dosing duration, absence of viral rebound observed to date, and favorable tolerability supports the strategic hypothesis that ratutrelvir may have utility in reducing post-acute sequelae of SARS-CoV-2 infection (Long COVID)." Dr. Redfield.
• "Collectively, we believe the interim data position ratutrelvir as a next-generation oral 3CL protease inhibitor with ritonavir-free administration, once-daily oral dosing, an improved tolerability profile, applicability to Paxlovid-ineligible populations, and potential relevance to long-COVID prevention strategies." Iain Dukes, MA D Phil, Chief Executive Officer, Traws Pharma.

Industry Context

The COVID-19 treatment market represents a potential multi-billion dollar opportunity. Ratutrelvir aims to address significant limitations of existing treatments like PAXLOVID, particularly for patients with contraindications to ritonavir or those experiencing viral rebound. Its ritonavir-free, once-daily profile could offer a substantial advantage in patient compliance and broader applicability, potentially impacting the standard of care for acute COVID-19 and Long COVID prevention, positioning Traws Pharma as a key player in the respiratory viral disease space.

Comparison to Industry Standards

• Ratutrelvir is directly compared to PAXLOVID (nirmatrelvir/ritonavir), a widely used COVID-19 antiviral treatment.
• Ratutrelvir demonstrated time-to-sustained symptom alleviation and resolution that was numerically comparable to PAXLOVID.
• No viral rebound events were observed in ratutrelvir-treated patients, contrasting with one rebound event (8.3%) in the PAXLOVID comparator arm.
• Ratutrelvir exhibited a more favorable tolerability profile with fewer reported adverse events (mild dyspepsia in 7.6% of patients) compared to PAXLOVID, where 30% of patients reported common adverse events like dysgeusia, dizziness, and dyspepsia.
• Ratutrelvir's ritonavir-free nature allows it to be administered to patients ineligible for ritonavir-boosted regimens, addressing a significant unmet medical need that PAXLOVID cannot.
• Ratutrelvir's once-daily oral dosing regimen offers a potential convenience advantage over PAXLOVID's twice-daily regimen.

Stakeholder Impact

• Shareholders: Positive interim data could lead to increased investor confidence and potential share price appreciation due to the promising clinical profile and market opportunity.
• Patients: Ratutrelvir offers a potentially safer and more broadly applicable treatment option for COVID-19, especially for those ineligible for PAXLOVID or concerned about viral rebound.
• Healthcare Providers: A new ritonavir-free, once-daily treatment with a favorable tolerability profile could simplify prescribing and improve patient adherence.
• Competitors: PAXLOVID (Pfizer) faces a potential new competitor with a differentiated profile, particularly regarding adverse events and rebound, which could impact its market share.

Next Steps

• Completion of enrollment and follow-up for the ongoing Phase 2 study of ratutrelvir.
• Reporting of final data analysis for the Phase 2 study in January 2026.
• Continued clinical evaluation of ratutrelvir in both acute COVID-19 and in studies designed to better understand its potential impact on longer-term outcomes (Long COVID).
• Actively seeking development and commercialization partners for legacy clinical oncology programs (rigosertib and narazaciclib).

Key Dates

Recommendation

The positive interim Phase 2 data for ratutrelvir, demonstrating comparable efficacy to PAXLOVID with a superior safety profile and no observed viral rebound, represents a significant de-risking event for Traws Pharma. The ability to treat PAXLOVID-ineligible patients addresses a substantial unmet market need. The ritonavir-free, once-daily dosing offers clear advantages. While preliminary, these results strongly suggest a high potential for ratutrelvir to become a leading COVID-19 treatment, justifying a "strong buy" recommendation for long-term investors given the multi-billion dollar market opportunity and the company's pipeline.

Keywords

COVID-19, ratutrelvir, Mpro inhibitor, 3CL protease inhibitor, ritonavir-free, PAXLOVID, antiviral, clinical trial, Phase 2, biopharmaceutical, Traws Pharma, SARS-CoV-2, Long COVID, drug development